At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 336 enrolled
Drug / intervention
SB-480848 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An International, Multicenter, Randomized, Placebo-controlled, Parallel-group, 1 Year Treatment, Integrated Biomarkers and Imaging Study in Subjects With Angiographically Documented Coronary Heart Disease (CHD) to Examine the Effects of the Novel Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor SB-480848 on Intermediate Cardiovascular Endpoints, Patient Safety and Tolerability
In Brief
A Phase 2 clinical trial evaluating SB-480848 and SB-480848 matching placebo for Atherosclerosis. Completed, enrolled 336 participants across 26 sites in 11 countries.
Detailed Summary
IBIS-2 is a study using SB-480848 versus placebo in subjects with angiographically documented coronary heart disease. Endpoints include coronary imaging, endothelial function, biomarkers, safety and tolerability.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtherosclerosis
CountriesAustria, Belgium, Czechia, Denmark, France, Germany, Netherlands, Norway, Poland, Spain, Switzerland
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2005
First PostedDec 2005
Primary CompletionAug 2007
TodayJul 2026
First PostedDec 23, 2005
Enrollment StartNov 10, 2005
Primary CompletionAug 28, 2007
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 20.5 years ago
Interventions
SB-480848drug
SB-480848 is available as enteric-coated, free-base micronized tablet
SB-480848 matching placebodrug
Placebo is available as enteric-coated, free-base micronized tablet